emtricitabine; tenofovir alafenamide fumarate: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Gilead Sciences Inc	DESCOVY	emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	208215	NDA	Gilead Sciences, Inc.	61958-2002-1	30 TABLET in 1 BOTTLE, PLASTIC (61958-2002-1)	2016-04-04
Gilead Sciences Inc	DESCOVY	emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	208215	NDA	Gilead Sciences, Inc.	61958-2002-2	30 TABLET in 1 BLISTER PACK (61958-2002-2)	2016-04-04
Gilead Sciences Inc	DESCOVY	emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	208215	NDA	Gilead Sciences, Inc.	61958-2005-1	30 TABLET in 1 BOTTLE, PLASTIC (61958-2005-1)	2022-01-07
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 29, 2025

Introduction

The global demand for antiretroviral medications, particularly Emtricitabine (FTC) and Tenofovir Alafenamide Fumarate (TAF), continues to surge owing to their pivotal role in HIV therapy and prophylaxis. As these drugs are integral to combination regimens such as Atripla and Descovy, understanding their suppliers provides critical insight for stakeholders across pharmaceutical, healthcare, and investment sectors. This article delineates the primary suppliers manufacturing Emtricitabine and Tenofovir Alafenamide Fumarate, explores the manufacturing landscape, and examines emerging trends in supplier dynamics.

Overview of Emtricitabine and Tenofovir Alafenamide Fumarate

Emtricitabine (FTC), a nucleoside reverse transcriptase inhibitor (NRTI), inhibits HIV replication by incorporating into viral DNA and causing chain termination. Approved since 2003 by the FDA, FTC remains a cornerstone in antiretroviral therapy (ART).

Tenofovir Alafenamide Fumarate (TAF), a prodrug of tenofovir, offers superior renal and bone safety profiles compared to Tenofovir Disoproxil Fumarate (TDF). TAF was approved in 2015 and has quickly become preferred in combination therapies due to its improved tolerability.

Key Suppliers for Emtricitabine

1. Jinzhou Pharma (Jilin, China)
Jinzhou Pharma is one of the dominant manufacturers producing Emtricitabine globally. It supplies API (Active Pharmaceutical Ingredient) and finished dose forms, primarily serving markets in China and Asia. Their API manufacturing facilities comply with international standards such as cGMP and ISO.

2. Teva Pharmaceutical Industries (Israel)
Teva is a leading global generic drug manufacturer with significant capacity for Emtricitabine APIs and formulations. The company’s legacy in antiviral production positions it as a reliable supplier, with products distributed worldwide.

3. Sun Pharmaceutical Industries (India)
Sun Pharma manufactures Emtricitabine as part of its antiretroviral portfolio. Their formulations are supplied across emerging markets, supported by robust manufacturing facilities adhering to global standards.

4. Aurobindo Pharma (India)
Aurobindo has expanded its antiviral API portfolio, including Emtricitabine, meeting regional demand through its vertically integrated manufacturing processes.

5. Dr. Reddy’s Laboratories (India)
Dr. Reddy’s produces Emtricitabine APIs and compliance-certified formulations, especially targeting markets in Latin America and Africa.

Key Suppliers for Tenofovir Alafenamide Fumarate

1. Gilead Sciences (USA)
Gilead, the original developer of TAF, manufactures and supplies the API through its manufacturing facilities in the USA and Europe. Gilead’s proprietary control over TAF production involves advanced synthesis processes and strict quality controls, contributing to its market dominance.

2. China-based Manufacturers (e.g., Zhejiang Huahai Pharmaceutical, Shanghai Fosun Pharmaceutical)
Chinese pharmaceutical companies have rapidly scaled up TAF manufacturing capacity. While some produce generic-grade TAF, others develop APIs compatible with Gilead’s formulations, often under licensing agreements or through independent development initiatives.

3. Cipla Limited (India)
Cipla manufactures TAF APIs and finished products, primarily targeting emerging markets. Their manufacturing facilities demonstrate cGMP compliance, and they maintain strategic licensing agreements with global innovator companies.

4. Mylan/Mylan-GSK (EpiC®) (USA/India)
Mylan has expanded its antiviral API portfolio and formulations, supplying generic TAF-based products through strategic licensing and vertical integration.

5. Dr. Reddy’s Laboratories (India)
Dr. Reddy’s has developed TAF APIs following licensing agreements and adheres to international manufacturing standards, positioning it as a key player in the supply chain.

Emerging and Strategic Trends in Supplier Dynamics

Licensing and Partnerships: Gilead’s licensing of TAF production to global generic manufacturers like Cipla, Mylan, and Dr. Reddy’s has democratized access while allowing for diverse supply sources. This strategy mitigates supply chain risks and enhances market competitiveness.
Manufacturing Capacity Expansion: Multiple Asian manufacturers have scaled up API production to meet rising global demand, especially in low- and middle-income countries. This expansion often follows technology transfers and quality compliance upgrades.
Regulatory and Quality Standards: Suppliers adhere to stringent cGMP standards, with many obtaining WHO prequalification and US/EU FDA approvals, ensuring quality and safety for global distribution.
Patent and Patent-Expiry Effects: The expiration or imminent expiration of patents influences supplier activity, with generic manufacturers increasing production capacity and diversified supply sources.
Vertical Integration and R&D Investments: Larger firms like Gilead invest heavily in R&D and vertical integration to maintain control over manufacturing processes, while generic players focus on cost-effective innovation.

Supply Chain Considerations for Stakeholders

Quality Assurance: Procurement decisions should prioritize suppliers with validated manufacturing processes, WHO prequalification, and regulatory approvals to ensure therapeutic efficacy and safety.
Supply Security: Diversification of suppliers mitigates risks associated with geopolitical tensions, regulatory disruptions, or manufacturing setbacks.
Pricing Dynamics: Competition among suppliers, especially with increased capacity in emerging markets, is leading to price reductions and more affordable access, particularly in resource-limited settings.
Intellectual Property and Licensing: Understanding licensing agreements is vital to anticipate supply availability, especially as patent exclusivities wane.

Conclusion

The supply landscape for Emtricitabine and Tenofovir Alafenamide Fumarate reflects a globalized industry marked by a mix of innovator firms, licensed generics, and regional manufacturers. Gilead remains the principal API supplier for TAF, leveraging advanced manufacturing capabilities, while numerous Asian firms have scaled up production of both APIs and formulations, driven by licensing agreements and market demand. Strategic diversification, quality compliance, and regulatory alignment are crucial to securing robust supply chains for these essential antiretroviral drugs.

Key Takeaways

Gilead Sciences dominates the TAF API supply chain but licensed production to key global generic manufacturers, expanding access.
Asian generic manufacturers such as Cipla, Mylan, and Dr. Reddy’s are vital suppliers, especially for emerging markets.
Regulatory standards and quality assurance are essential criteria in supplier selection to ensure drug safety and efficacy.
The ongoing expansion of manufacturing capacity in Asia is increasing supply security and driving down costs.
Licensing agreements influence supply dynamics, with patent expirations creating opportunities for new entrants and increased competition.

FAQs

1. Who are the primary global suppliers of Emtricitabine?
Major suppliers include Jinzhou Pharma (China), Teva (Israel), Sun Pharma (India), Aurobindo Pharma (India), and Dr. Reddy’s Laboratories (India), all providing APIs and formulations.

2. Which companies manufacture Tenofovir Alafenamide Fumarate?
Gilead Sciences is the original manufacturer, with licensed production by Cipla, Mylan, Dr. Reddy’s, and several Chinese firms expanding capacity for the API.

3. Are there regional differences in supplier quality standards?
Yes. While most international suppliers adhere to cGMP standards, differences in regulatory oversight may influence quality assurance, emphasizing the need for quality certifications like WHO prequalification.

4. How do patent laws affect TAF supply?
Patent protections initially limited generic production, but patent expirations and licensing agreements now facilitate increased manufacturing by generic companies.

5. How can stakeholders assess supplier reliability?
Stakeholders should evaluate regulatory certifications, manufacturing capacity, compliance with international standards, and history of quality assurance documentation.

Sources

U.S. Food and Drug Administration (FDA). Emtricitabine and Tenofovir Alafenamide Fumarate approval history.
Gilead Sciences. Official API manufacturing and licensing information.
World Health Organization (WHO). Prequalification of Antiretroviral Drugs.
Deloitte. Global Pharmaceutical Supply Chain Trends.
Recent industry filings and licensing agreements, including company press releases and regulatory submissions.

Suppliers and packagers for generic pharmaceutical drug: emtricitabine; tenofovir alafenamide fumarate